New antidote for smoke-related cyanide toxicity shows promise

Smoke inhalation is the major cause of death in fire victims due to cyanide poisoning. However, new research presented at CHEST 2012, the annual meeting of the American College of Chest Physicians, shows that a new antidote, cobinamide, may help reverse the effects of cyanide toxicity.

Researchers from multiple institutions, including the University of California Irvine Medical Center, exposed six ventilator-supported New Zealand white rabbits to cold smoke breaths until toxic carbon monoxide levels were achieved, concurrent with intravenous cyanide infusion.

Intravenous cobinamide was administered in treatment arm animals and compared with control responses.

Results showed that intravenous cobinamide reversed cyanide toxicity in these animals in the face of smoke-induced carbon monoxide exposure, without evident adverse effects.

Researchers concluded that cobinamide shows promise as a potential antidote for in victims and that it could potentially be administered in mass casualty exposure scenarios.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Rapid response in cases of smoke poisoning

Sep 04, 2012

Smoke poisoning can be caused by a number of things, including cyanides, the salts of hydrocyanic acid. Because the quick diagnosis and treatment of victims with cyanide poisoning is critical and often lifesaving, ...

Recommended for you

Merck completes sale of consumer unit to Bayer

3 hours ago

Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...

Viagra ads target women for first time

Sep 30, 2014

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments